It is not just Dr. Linda Liau that states patients are living longer than expected. Additionally, Dr. Bosch excitedly made a similar observation in the information arm. Those patients, particularly the double rapid progressors, were not included in the phase III trial because it was thought DCVax could not help them; however, results there gave Dr. Bosch a different impression than he originally anticipated. His best hypothesis for this unexpected result was an improved dosing regimen.